Tamoxifen
- Generic Name
- Tamoxifen
- Brand Names
- Soltamox
- Drug Type
- Small Molecule
- Chemical Formula
- C26H29NO
- CAS Number
- 10540-29-1
- Unique Ingredient Identifier
- 094ZI81Y45
- Background
Tamoxifen is a non-steroidal antiestrogen used to treat estrogen receptor positive breast cancers as well as prevent the incidence of breast cancer in high risk populations. Tamoxifen is used alone or as an adjuvant in these treatments. Tamoxifen may no longer be the preferred treatment for these types of cancers as patients generally have better survival, s...
- Indication
Tamoxifen is indicated to treat estrogen receptor positive metastatic breast cancer in adults, as an adjuvant in the treatment of early stage estrogen receptor positive breast cancer in adults, to reduce the risk of invasive breast cancer after surgery and radiation in adult women with ductal carcinoma in situ.
- Associated Conditions
- Breast Cancer, Contralateral Breast Cancer, Desmoid Tumor, Early Stage Estrogen Receptor (ER) Positive Breast Cancer, Gynecomastia, Invasive Breast Cancer, Ovarian Cancer, Puberty, Precocious, Metastatic Estrogen Receptor Positive Breast Cancer
- Associated Therapies
- Ovulation induction therapy
Neoadjuvant Treatment of Breast Cancer
- First Posted Date
- 2021-11-23
- Last Posted Date
- 2021-11-23
- Lead Sponsor
- National Institute of Oncology, Hungary
- Target Recruit Count
- 300
- Registration Number
- NCT05131893
- Locations
- 🇭🇺
National Institute of Oncolgy, Budapest, Hungary
Study of Amcenestrant (SAR439859) Versus Tamoxifen for Patients With Hormone Receptor-positive (HR+) Early Breast Cancer, Who Have Discontinued Adjuvant Aromatase Inhibitor Therapy Due to Treatment-related Toxicity
- Conditions
- Interventions
- First Posted Date
- 2021-11-22
- Last Posted Date
- 2023-06-22
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 3
- Registration Number
- NCT05128773
- Locations
- 🇨🇳
Investigational Site Number :1561599, Haikou, China
🇨🇱Investigational Site Number :1521622, Santiago, Reg Metropolitana De Santiago, Chile
Umbrella Trial Testing Integrative Subtype Targeted Therapeutics in Estrogen Receptor Positive, HER2-Negative Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2021-11-01
- Last Posted Date
- 2024-07-11
- Lead Sponsor
- Stanford University
- Target Recruit Count
- 19
- Registration Number
- NCT05101564
- Locations
- 🇺🇸
Stanford University, Stanford, California, United States
A Phase 2 Single-Arm Open-Label Pilot Trial Evaluating Zanidatamab (ZW25) in Patients With Early Stage HER2/Neu Positive (HER2+) Breast Cancer (BC)
- Conditions
- Interventions
- First Posted Date
- 2021-09-05
- Last Posted Date
- 2024-10-08
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 20
- Registration Number
- NCT05035836
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Investigating the Potential Role of a Novel Quadrate Combination Therapy Mifepristone(Antiprogestrone), Tamoxifen, Retinoic Acid and Cannabidiol ( Selective Cyp 26 Inhibitor) for Treating Early Breast Cancer.
- First Posted Date
- 2021-08-23
- Last Posted Date
- 2021-08-23
- Lead Sponsor
- Mahmoud Ramadan mohamed Elkazzaz
- Target Recruit Count
- 160
- Registration Number
- NCT05016349
A Trial of Early Detection of Molecular Relapse With Circulating Tumour DNA Tracking and Treatment With Palbociclib Plus Fulvestrant Versus Standard Endocrine Therapy in Patients With ER Positive HER2 Negative Breast Cancer
- First Posted Date
- 2021-08-02
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- Royal Marsden NHS Foundation Trust
- Target Recruit Count
- 1100
- Registration Number
- NCT04985266
- Locations
- 🇬🇧
Barnet Hospital, London, Barnet, United Kingdom
🇬🇧Royal Sussex Hospital, Brighton, United Kingdom
🇬🇧Velindre Cancer Centre, Cardiff, United Kingdom
Dose-determining and Dose-confirmatory Study to Investigate the Optimal Dose of Tamoxifen in Breast Cancer Patients According to Genotype Status of TCF20 rs932376
- First Posted Date
- 2021-07-14
- Last Posted Date
- 2024-02-01
- Lead Sponsor
- National Cancer Centre, Singapore
- Target Recruit Count
- 75
- Registration Number
- NCT04961632
- Locations
- 🇸🇬
National Cancer Centre, Singapore, Singapore
Ovarian Suppression Evaluating Subcutaneous Leuprolide Acetate in Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2021-05-28
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- Tolmar Inc.
- Target Recruit Count
- 250
- Registration Number
- NCT04906395
- Locations
- 🇺🇸
Marin Cancer Care, Inc, Greenbrae, California, United States
🇺🇸Cypress Hematology and Oncology, Parker, Colorado, United States
🇺🇸Cancer Care Centers of Brevard, Inc., Melbourne, Florida, United States
Analysis of Therapy Sequence in Women With HR+, HER2 - mBC in Moscow: A Multicenter Retrospective Observational Study.
- First Posted Date
- 2021-04-21
- Last Posted Date
- 2021-04-21
- Lead Sponsor
- Blokhin's Russian Cancer Research Center
- Target Recruit Count
- 1000
- Registration Number
- NCT04852081
- Locations
- 🇷🇺
N.N. Blokhin National Medical Research Center of Oncology, Moscow, Russian Federation
Tamoxifen Versus Etoposide After First Recurrence in GBM Patients
- First Posted Date
- 2021-02-21
- Last Posted Date
- 2024-06-12
- Lead Sponsor
- AHS Cancer Control Alberta
- Target Recruit Count
- 60
- Registration Number
- NCT04765098
- Locations
- 🇨🇦
Cross Cancer Institute, Edmonton, Alberta, Canada
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.